A physiologically based pharmacokinetic (PBPK) model was developed that provides a comprehensive description of the kinetics of trichloroethylene (TCE) and its metabolites, trichloroethanol (TCOH), trichloroacetic acid (TCA), and dichloroacetic acid (DCA), in the mouse, rat, and human for both oral and inhalation exposure. The model includes descriptions of the three principal target tissues for cancer identified in animal bioassays: liver, lung, and kidney. Cancer dose metrics provided in the model include the area under the concentration curve (AUC) for TCA and DCA in the plasma, the peak concentration and AUC for chloral in the tracheobronchial region of the lung, and the production of a thioacetylating intermediate from dichlorovinylcysteine in the kidney. Additional dose metrics provided for noncancer risk assessment include the peak concentrations and AUCs for TCE and TCOH in the blood, as well as the total metabolism of TCE divided by the body weight. Sensitivity and uncertainty analyses were performed on the model to evaluate its suitability for use in a pharmacokinetic risk assessment for TCE. Model predictions of TCE, TCA, DCA, and TCOH concentrations in rodents and humans are in good agreement with a variety of experimental data, suggesting that the model should provide a useful basis for evaluating crossspecies differences in pharmacokinetics for these chemicals. In the case of the lung and kidney target tissues, however, only limited data are available for establishing cross-species pharmacokinetics. As a result, PBPK model calculations of target tissue dose for lung and kidney should be used with caution.
Introduction
Physiologically based pharmacokinetic (PBPK) modeling is widely held to be a useful methodology for improving the accuracy of chemical risk assessment (1) (2) (3) (4) (5) (6) . The goal of PBPK modeling is to simulate the uptake, distribution, metabolism, and elimination of a chemical in an organism, using as realistic a description of the relevant physiology and biochemistry as is necessary and feasible (7) (8) (9) (10) . For its use in risk assessment, PBPK modeling attempts to describe the relationship between external measures of exposure (e.g., amount administered or concentration in air) and internal measures of biologically effective dose (e.g., amount metabolized or concentration of an active metabolite in the tissue displaying the toxic response) in both the experimental animal and the human (11, 12) .
Simple pharmacokinetic approaches have occasionally been used by regulatory agencies in risk assessment; for example, the most recent U.S. Environmental Protection Agency (U.S. EPA) cancer risk estimates for trichloroethylene (TCE) were derived using estimates of metabolized dose (13, 14) . The recent U.S. EPA guidelines for the application of inhalation dosimetry in the derivation of inhalation reference concentrations (15) also make use of pharmacokinetic principles. However, the only case to date where a regulatory agency has used a full PBPK approach in a published risk assessment was in the U.S. EPA's latest revision of its inhalation risk assessment for methylene chloride (16) . The decision to use the PBPK approach in this case was made only after a period of considerable controversy, including a workshop sponsored by the National Academy of Sciences at which the usefulness of PBPK modeling for chemical risk assessment was discussed. The scientific consensus following the workshop was that "relevant PBPK data can be used to reduce uncertainty in extrapolation and risk assessment" (1) . In 1989, after a detailed multiagency evaluation of the available PBPK information and a review by the U.S. EPA Scientific Advisory Board, the U.S. EPA revised the inhalation unit risk and riskspecific air concentrations for methylene chloride in its Integrated Risk Information System (IRIS) (17) database, citing the PBPK model of Andersen et al. (18) . The resulting risk estimates were lower than those obtained by the default approach by nearly a factor of 10. Application of the PBPK model for methylene chloride in a cancer risk assessment for occupational exposure has also been described (19) (20) (21) , and a modified version of the model was used by the Occupational Safety and Health Administration (OSHA) in their rulemaking for methylene chloride (22) .
Risk assessments using PBPK models have also been proposed for many other chemicals, including not only TCE (23) (24) (25) (26) , but also perchloroethylene (PERC) (24,27,28), ethylene dichloride (29) , vinyl chloride (26, (30) (31) (32) , dioxane (33, 34) , chloroform (35) , benzene (36) , and ethyl acrylate (37) . However, apart from the case with methylene chloride described above, there still have been no risk assessments published by a regulatory agency in which a PBPK model was used for estimating target tissue dose. Part of the reason for the slow progress of incorporating PBPK modeling in cancer risk assessment is the concern of regulatory agency risk assessors about uncertainties in its implementation.
The potential impact of uncertainty in pharmacokinetic risk assessment has been a subject of some controversy (19) (20) (21) (38) (39) (40) (41) (42) (43) . The purpose of the study reported here was to develop a PBPK model for TCE that included as complete a description as possible of all of the metabolites and target tissues that are relevant to the toxicity and carcinogenicity of TCE and to evaluate the suitability of the resulting model to provide dosimetry for each of the target tissues in support of a comprehensive pharmacokinetic risk assessment for TCE. For completeness, aspects of both the cancer and noncancer risk assessment contexts pertinent to the development and evaluation of the PBPK model are discussed in this article. However, a companion article in this same issue provides a detailed description of the application of the PBPK model in a noncancer risk assessment for TCE (44) . Therefore, the discussions in this article will focus primarily on the cancer end points.
Toxicity and Carcinogenicity ofTCE TCE produces noncancer toxicity in a variety of tissues; principal noncancer end points include neurological, hepatic, renal, immunological, and developmental effects (45) (46) (47) . The American Conference of Government Industrial Hygienists (ACGIH) threshold limit value (TLV) for TCE is currently 50 ppm as an 8-hr time-weighted average (TWA), based on central nervous system (CNS) effects (headaches, fatigue, irritability), with a short-term exposure limit of 200 ppm to protect against its anesthetic effects (48). In 1989, as part of a major rulemaking that promulgated standards for more than 200 chemicals, OSHA adopted a permissible exposure level (PEL) for TCE of 50 ppm as an 8-hr TWA based on the ACGIH TLV (49) . However, since the entire 1989 rulemaking has now been overturned by the courts, the PEL for TCE has returned to its previous value of a 100-ppm 8-hr TWA, also based on CNS effects.
TCE was widely used in industry for many years because of its relatively low toxicity, its excellent solvent properties, and its nonflammability. In recent years, however, use of TCE has been greatly reduced due to concerns regarding its carcinogenicity (46, 47) . Nevertheless, the question of the human carcinogenicity of TCE remains controversial. Although a large number of studies have demonstrated tumors in animals following exposure to TCE, the relevance of these animal results to the question of the human carcinogenicity of TCE has frequently been challenged (50) (51) (52) . The ACGIH has classified TCE into Group A5, not suspected as a human carcinogen, based on a well-conducted, negative epidemiological study performed in an aircraft maintenance facility at Hill Air Force Base (Ogden, UT) (53, 54) . The International Agency for Research on Cancer (IARC), on the other hand, classifies TCE into Group 2A, probably carcinogenic to humans, based on their assessment of sufficient data in animals and limited data in humans (55) . The human evidence considered significant by IARC was the consistency of an association of TCE exposure with slightly increased incidences of liver/biliary tract tumors and non-Hodgkins lymphoma in studies of three cohorts in the United States (53) , Sweden (56) , and Finland (57) , despite the fact that all three studies were characterized as negative by the original investigators because the increases were not statistically significant.
Requirements for a PBPK Model to Support TCE Risk Assessments Quantitative cancer risk estimates for TCE are currently based on animal bioassays, specifically liver and lung tumors in mice. In 1983, the U.S. EPA calculated unit risks for TCE of 4.1 x 106 (pg/m3)-1 for inhalation and 0.54 x 10-(pg/L)-1 for drinking water using data on the incidence of liver tumors in male B6C3F, mice given TCE in an oil vehicle by gavage (58, 59) ; the linearized multistage model (60) was used with a calculation of absorbed TCE dose scaled by body surface area (BSA) to obtain these estimates (61) . In 1985, lower unit risks of 1.3 x 106 (pglm3)-1 for inhalation and 0.32 x (jg/L)1' for drinking water were recalculated on the basis of the same oral bioassays, using the results of pharmacokinetic studies (50, 62, 63) to calculate total metabolized dose in both animals and humans, rather than absorbed dose. The BSA adjustment was still applied to obtain the human equivalent dose (13) . In 1987, the U.S. EPA calculated a new inhalation unit risk of 1.7 x 10-(ig/m3)-1 based on the incidence of mouse liver and lung tumors in inhalation bioassays (64) (65) (66) , again using a calculation of metabolized dose and the BSA adjustment (16) . Statistically significant increases in the incidence of renal tubular cell adenoma and carcinoma have also been observed in male Fischer 344 (F344) rats exposed to TCE by gavage (67) .
Although not yet used in a quantitative risk assessment for TCE, the incidences of these kidney tumors in rats have raised concern, since they represent a rare tumor that has also been associated with human occupational exposure to TCE (68) .
For each of these three target tissuesliver, lung, and kidney-there is evidence that the carcinogenicity of TCE may be associated with one or more of its metabolites: trichloroacetic acid (TCA) and dichloroacetic acid (DCA) in the liver (69, 70) , chloral (CHL) in the lung (71) , and 1,2-dichlorovinylcysteine (DCVC) in the kidney (72) . Thus, to be useful in a comprehensive cancer risk assessment for TCE, a PBPK model should include at least three target tissues-liver, lung, and kidney-along with a description of the kinetics of the metabolites imputed to play a role in the carcinogenic activity.
Several target tissues have also been identified for the noncancer toxicity of TCE, including the liver (73) , kidney (65, 66) , CNS (74) , immune system (75, 76) , and developing fetus (77) . As in the case of the carcinogenicity of TCE, several of these noncancer end points appear to be associated with exposure to the metabolites of TCE rather than to the parent chemical itself (73, 78) . In addition to the metabolites mentioned above with regard to the carcinogenicity of TCE, it was felt (43) that a PBPK model developed to support a noncancer risk assessment for TCE should also include a description of the kinetics of trichloroethanol (TCOH), a major metabolite of TCE that has been suggested to be responsible for the observed neurological effects of chloral hydrate (79) .
Previous PBPK Modeling ofTCE
A number of PBPK models have been developed for TCE. However, most are only parent chemical models; that is, they provide a pharmacokinetic description ofTCE itself, but do not include an explicit description of the pharmacokinetics of any of the metabolites (23, 24, (80) (81) (82) (83) (84) (85) (86) . These models have been used successfully for predicting TCE concentrations in the blood and tissues (86) , for calculating the respiratory input from inhalation exposures (81, 82, 85) , and for investigating the impact of variations in the physiological or biochemical parameters on the kinetics ofTCE (80, 83, 84) . Parent chemical models have also been employed to calculate total metabolized dose in support of a cancer risk assessment for TCE (23, 24) . However, these parent chemical models cannot be used for predicting tissue exposure to specific metabolites.
Models of both TCE and its metabolites have also been developed. In a series of publications, Sato and co-workers have described the use of a simple PBPK model to study the kinetics of TCE and its metabolites in humans (87) , to evaluate the impact of changes in physiological factors (88) and environmental factors (89) on the kinetics of TCE in the human, and to predict the effects of interactions with ethanol consumption on TCE kinetics (90) . However, the structure of these models would not support the animalto-human extrapolation of pharmacokinetic dose metrics needed for risk assessment. Fisher and co-workers developed a PBPK model for TCE and its principal metabolite, TCA, in the pregnant (91) and lactating (92) rat, as well as in the mouse (93) . These rodent models, together with a similar model of TCE and TCA in the human (94) , served as the basis for a PBPK-based risk assessment for TCE liver carcinogenicity (25) based on either total metabolism or AUC for TCA. These models provided the first successful cross-species pharmacokinetic description for a metabolite of TCE. The model development performed in the current study builds on the work of Fisher and Allen (25) by adding limited descriptions of additional metabolites (TCOH, DCA, CHL, DCVC) and target tissues (lung and kidney).
Metabolism ofTCE
The following discussion summarizes the experimental evidence for the nature of the pharmacokinetics and metabolism of TCE, which formed the basis for the decisions that were made regarding the structure and parameterization of the Figure 1 . The major oxidative pathway, which takes place primarily (but not exclusively) in the liver, is shown to the right of the diagram; the minor glutathione-dependent pathway, which involves several locations induding the liver and kidney, is shown to the left.
Oxidative metabolism. The primary route of metabolism for TCE, shown on the right side of the diagram in Figure 1 , is oxidation via the microsomal mixed-function oxidase (MFO) system, now referred to as cytochrome P450, or CYP (96) (97) (98) (99) (100) (101) (102) . A minor pathway for TCE metabolism involving conjugation with glutathione (GSH) by glutathione transferase (GST) has also been observed (103) . This pathway, which is shown on the left side ofthe diagram, will be described in the section on conjunctive metabolism.
The principal oxidative metabolite formed in vitro is CHL (96, 97, 100) , which is subsequently reduced to TCOH in the cytosol or oxidized to TCA in either the cytosol or mitochondria (96) . CHL is not stable in vivo, and circulating concentrations are relatively low compared to its breakdown products, TCA and TCOH (50) . Within a few hours of the administration of 50 mglkg chloral hydrate to a child, the rapid initial dearance of CHL was essentially complete. Subsequent blood concentrations parallel the time course for TCOH but are approximately an order of magnitude lower, suggesting a continuing production of CHL from TCOH (104) .
The principal circulating metabolite of TCE in the blood is TCA, which accumulates in the body due to protein binding (105) and slow excretion (106) , whereas TCOH is readily excreted (107, 108) . TCA appears to be derived both directly from CHL and indirectly from TCOH (107) (108) (109) . TCE is much more extensively metabolized in the mouse than in the rat, whether TCE is administered orally (50) or by inhalation (91) .
Based on both in vitro and in vivo studies, the metabolism ofTCE has been suggested to consist of oxidation of TCE to CHL by the MFO system, followed by either oxidation of CHL to TCA by an aldehyde oxidase (also known as chloral dehydrogenase) or reduction to TCOH by alcohol dehydrogenase (ADH) with subsequent glucuronidation. Oxidation of TCOH to TCA by the MFO system has also been proposed (110 description, oral co-administration of ethanol inhibited the metabolism of inhaled TCE to TCOH by more than 50% and the production of TCA was essentially abolished while ethanol was present (110) . A similar study in rats demonstrated qualitatively similar, but quantitatively much less remarkable, effects of ethanol co-administration on the kinetics of orally administered TCE (111) .
Inhalation exposures of human volunteers to TCE concentrations from 27 to 201 ppm showed no evidence of metabolic saturation or of a change in the proportion of TCA to TCOH (112) . Saturation of TCE metabolism has been observed in mice, rats, and dogs (66, 113) . The relative proportion of the major metabolites does not appear to be a strong function of dose. However, repeated dosing does appear to increase the production of TCA at the expense of TCOH (114) , and the relative production of CO2 increases with increasing dose in mice (115 (117) . A study of TCE metabolism in nonhuman primates (118) found that TCA was partially excreted as the glucuronide, particularly at longer times after dosing. The authors suggest that since the detection of TCA glucuronide had not been reported previously, TCA excretion may have been under-reported in earlier studies (such as the human study cited above). The glucuronidation of TCA is supported by the observation that TCA is excreted in the bile of rats and mice (114) . Urinary excretion represents the major route of elimination of the metabolites; fecal excretion, in the form of TCOH glucuronide, accounts for less than 5% of the total (118) . The low fecal excretion is apparently associated to some extent with enterohepatic recirculation of TCOH (i.e., biliary excretion of the glucuronide, followed by hydrolysis and reabsorption of TCOH), which has also been suggested to occur in rats (119) . DCA has been identified as a minor urinary metabolite of TCE (on the order of 1%) in both rats and mice (114, 115, 117, 120) , whereas MCA appears to be present at less than 0.1% (114) (124) . Significantly, the clearance in humans appears to be much more rapid than would be expected from allometric scaling of animal data. In a comparative study (122) , the half-lives in rats, dogs, and humans were 2.1-4.4 hr, 17.1-24.6 hr, and 0.33-0.6 hr, respectively. The extremely high rate of metabolism of DCA in humans is probably responsible for the failure of investigators to detect it as a urinary metabolite ofTCE.
Studies have shown that DCA is produced from TCA (67) . In addition, DCA is produced in a roughly linear fashion from PERC (28, 125) at levels consistent with production from TCA, the principal metabolite of PERC. An analysis of data on the dose-response and elimination kinetics of DCA formed from TCE led to the conclusion that another source of DCA was required in addition to TCA, but that the data were inconsistent with the second source being the initial oxidation step (126) . Instead, the production of DCA from TCOH was hypothesized. A metabolic study of TCA and DCA in rats and mice (67) found that DCA was more rapidly metabolized than TCA. More than 50% of the administered TCA from an oral dose was excreted unchanged in the urine as compared to only 2% of administered DCA. Plasma concentration-time curves for TCA were similar in mice and rats, whereas those for DCA were greater in rats than in mice, both when DCA was administered and when it was derived from TCA.
There is evidence that repeated exposure to high concentrations of DCA inhibits its own metabolism. In studies with human volunteers (124, 127) , the excretion half-life for DCA increased 2-to 6-fold following repeated intravenous doses of DCA on the order of 10-50 mg/kg. Inhibition was only slowly reversible, taking from 1 week to greater than 3 months. In the rat, but not the mouse, exposure to 2 g/L DCA in drinking water for 14 days curtailed metabolic production of CO2 from DCA by more than an order of magnitude and increased the excretion half-life by roughly 4-fold (128) .
It has recently been reported that under some conditions DCA can be artificially produced from TCA in blood samples as an artifact of the analysis. If acidification of the sample is performed rapidly after collection of the sample before the hemoglobin iron has been oxidized by exposure to air, DCA can be generated from TCA present in the sample (129) . This artifact may have compromised some of the data reported on DCA plasma concentrations following administration of TCA or TCE (66, 67) .
Metabolism in the lung. As with most chemicals, the preponderance of the metabolic dearance of TCE appears to take place in the liver. It has been demonstrated, however, in studies with an isolated, ventilated perfused lung preparation (130) , that the male F344 rat lung also possesses a limited oxidative metabolic capability for TCE. Although the affinity (K,, for the lung metabolism observed in that study was similar to the affinity observed in the liver, the capacity (Vmax) of the lung metabolism was less than 1% of the capacity of the liver. These results suggest that lung metabolism is not an important contributor to total in vivo metabolism in the rat and that the rat lung does not possess a significant first-pass (presystemic) clearance capability for inhaled TCE. However, these results do not rule out the possibility that metabolism in the lung could produce sufficient local exposure to metabolites to produce toxicity and/or carcinogenicity.
Conjugative metabolism. A small proportion of TCE appears to be metabolized by enzymatic conjugation with GSH, principally by GST in the liver, followed by further metabolism in the kidney to the cysteine conjugate DCVC (131) . The GST metabolic pathway is shown on the left side of Figure 1 . Delivery of DCVC to the kidney may also be mediated by enterohepatic recirculation, in which GSH conjugate excreted in the bile is converted by gut bacteria to the cysteine conjugate, which is then reabsorbed (132) . The GSH conjugate has been identified both in vitro, with rat liver microsomes, and (at 5 nmol/L) in the bile of rats given 2.2 g/kg TCE in corn oil (103) . The cysteine conjugate also has been identified in the urine of animals dosed with TCE (72) .
The bioactivation of DCVC to a reactive and mutagenic thioacylating intermediate is performed by cysteine conjugate I-lyase in the kidney (133) . Although similar P-lyase activity has been measured in the kidney and liver, the two enzymes are distinct (134) . Detoxification and dearance of DCVC takes place by urinary excretion of the N-acetyl derivative (103, 135) . In a study with PERC (136) , it was determined that the excretion of the N-acetyl derivative was dose related (a higher fraction of N-acetyl derivative was excreted at doses where the oxidative pathway was saturated) and was significantly greater in the rat than in the mouse. However, measurements of acid-labile protein adducts associated with DCVC suggest that the activation of DCVC in the kidney may be as much as 12-fold greater in mice than in rats and that the kidney tissue exposure to DCVC-derived reactive species from oral dosing with TCE may be twice as great in the mouse as in the rat (137, 138) .
The activity of P-lyase has been measured in the liver and kidney of both humans and rats. One research group has reported a specific activity in human kidney on the order of 2.0-3.6 nmol/min/mg cytosol (139, 140 ), compared to 6.45-7.6 nmol/min/mg cytosol in the rat (134) . Another research group, however, has reported a maximum velocity (Vmax) of only 0.8 nmol/min/mg cytosol in the human, with an affinity (Ki) of 0.29 mM, compared to Vmax = 7.5 nmol/min/mg cytosol and Km = 1.6 mM in rat kidney cytosol in the same study (141) . Data for PERC on the relative activity of liver cytosolic GST and kidney cytosolic cysteine conjugate ,B-lyase suggest that the human activity of both enzymes is roughly 10-fold lower than that in the rat (136) . On the other hand, the specific activity of N-acetyltransferase in kidney cytosol appears to be very similar across species: 0.41 nmol/min/mg cytosol in the human, compared to 0.35-0.61 in the rat and 0.94 in the mouse (142) .
The fact that N-acetyl-DCVC has been identified in the urine of humans exposed to TCE both occupationally (142) and in controlled exposures (143) indicates that exposure of the kidney to DCVC does occur in the human. In the occupational study (142) , the concentrations of N-acetyl-DCVC in the workers' urine was about one-third of that measured in rats dosed orally with 50 mg/kg TCE. The ratio of N-acetyl-DCVC to TCA in the workers' urine ranged from 0.03 to 0.3, while in rats it ranged from 0.025 to 0.045, and in mice from 0.014 to 0.065. However, more recent data (143) CHL in the liver, but instead assumes that TCA and TCOH are formed in a fixed yield from the oxidative metabolism of TCE. In the model, TCOH can subsequently be oxidized to TCA, conjugated with glucuronic acid, or reduced to DCA. DCA can also be produced from the reduction of TCA. Biliary excretion of TCOH glucuronide and enterohepatic recirculation of free TCOH is described, with only the glucuronide being excreted in the urine. Dose metrics for use with the liver target tissue include the concentrations and AUC for DCA and TCA in the plasma, as well as a potency-weighted sum of the AUCs for DCA and TCA, which will be described in the discussion on dose metric uncertainty. The concentration and AUC for TCOH in the blood are also provided as a noncancer dose metric.
Conjugative metabolism. The model also includes a linear metabolic pathway representing conjugation of TCE by GST. The model implicitly assumes that all GSH conjugation of TCE in the liver leads eventually to the appearance of DCVC in the kidney. Clearance of DCVC by N-acetyltransferase into the urine is also modeled. Figure 2 , the kidney is not described separately in the parent chemical model. The partition coefficients for TCE were obtained from the work of Fisher and Allen (25, 94) and Fisher et al. (93); the partition coefficients for the gut and tracheobronchial tissues were assumed to be the same as those reported for the richly perfused tissues. The oral uptake parameters were estimated from data on the appearance of TCE and its metabolites in the blood following corn oil gavage in mice and rats (50) . For some parameters, identified in Table 1 (93, 109) . Since the model contains a large number of metabolic and clearance parameters, many of which are highly correlated, the parameter values estimated by this process (i.e., the kinetic parameters for TCA, TCOH, and DCA) cannot be considered to be unequivocally identified. However, an additional biological constraint was applied during the modeling by demanding that all parameters be essentially constant across exposure scenarios within a given species and (to the extent justified by the experimental data) across species. This constraint greatly reduces the likelihood that alternative parameterizations could demonstrate equivalent success in reproducing the entire body of data. Another constraint on the parameterization not obvious from the figures is that of the total TCOH extractable from the blood, roughly 80% is present as free TCOH in the human (110), whereas roughly 70-85% is present as glucuronide in the rodent (113, 126) . In the figures in this article, the model concentrations shown represent either free TCOH (in rodents) or total (in humans), corresponding to the experimental data provided.
It is informative to note the departures from simple allometric expectations that were required on the basis of the experimental data across species. As with most other xenobiotics, the mouse shows a relatively greater and more variable capacity (VMC) for oxidative metabolism ofTCE than the rat and human. Also in keeping with evidence from other P450 substrates, the affinity for oxidative metabolism of TCE in the human is roughly an order of magnitude less (i.e., the value of KM is larger) than in the rodents. A striking difference between humans and rodents, which was clearly demanded by the experimental data, was that the oxidation of TCOH to TCA appears to be a relatively high-affinity (small value of KMO), low-capacity (small value of VMOC) process in the rodent but low affinity, high capacity in the human. It may be that this disparity reflects the involvement of different enzymes (e.g., MFO in the rodent vs ADH in the human). The result of this species difference is that although the model uses a similar.value across species for PO (based on the initial split of TCA and TCOH from CHL), the apparent ratio of TCA to TCOH predicted (and observed) over the entire time frame of an exposure to TCE is much higher in the human than in the rodent. The capacity (VMG) for glucuronidation of TCOH in the human, on the other hand, is much lower than in the rodent, as reflected in the greatly different ratios of free TCOH to glucuronide in the blood, mentioned above. The prolonged time courses of TCOH in the human provide clear evidence of biliary excretion (KEHBC) and enterohepatic recirculation (KEHRC). Evidence for enterohepatic recirculation was equivocal in the rodents, however, with recirculation being required to reproduce some data, but being contradicted by other data in the same species.
The least well-characterized portion of the oxidative metabolism pathway is the description of the kinetics of DCA. The only species in which DCA has been reproducibly detected in the blood following TCE exposure is the mouse, and these data were used to obtain values for the production (VMRC and KMR) and clearance (VMDC and KMDC) in the mouse. (The artifactual production of DCA from TCA in blood samples, noted earlier in this report, may have compromised some of the data on DCA plasma concentrations used to parameterize the production and clearance of DCA in the mouse.) Assuming that the affinities (KMR and KMD) are constant across species, the capacities in the other species were estimated (for VMDC) from the reported half-lives of DCA across species (122), or (for VMRC in the human) from data on peak DCA concentrations in human subjects exposed to TCE by inhalation (148) . Since the clearance of DCA in the rat is actually slower than in the mouse (70), the capacity for production of DCA (VMRC) in the rat was set to the lower human value rather than that of the mouse to be consistent with the failure of investigators to observe DCA in the plasma of the rat following administration of TCE (69) . The renal clearance of DCA (KUDC) was assumed to be the same as that observed for TCA (KUTC) in the same species. As mentioned earlier, the most striking departure from allometric expectations for the kinetics of DCA is the extremely high clearance in the human compared to the other species.
Parameters for lung metabolism. The parameters in the PBPK model for predicting the lung dose metric are the capacity and affinity for the production of CHL (VMTBC and KMTB) and the capacity and affinity for its clearance (VMCTBC and KMCTB). In the model, the production of CHL in the tracheobronchial region was assumed to be associated with the P450 activity in that tissue. This is the assumption that was made in the pharmacokinetic risk assessment for methylene chloride (18) . The approach used in that risk assessment was also used to obtain the parameters in this case: the affinity in the lung was assumed to be the same as in the liver for the same species, and the relative capacity of the lung compared to the liver was determined on the basis of P450 activity measured with standard substrates (18) . Based on these data, P450 activity falls off much more rapidly with body weight than would be expected from allometric considerations. No data were available on the clearance of CHL in the lung across species; therefore, it was assumed to be a low-affinity, high-capacity enzyme system such as ADH. The parameters in the PBPK model were chosen such that concentrations of CHL in the lung of the mouse predicted by Environmental Health Perspectives * Vol 108, Supplement 2 * May 2000 the model were consistent with those observed in recent studies (149) . It was further assumed that the clearance of CHL in the lung scales across species according to allometric expectations (i.e., by body weight to the 3/4 power). This assumption leads to much lower CHL concentrations in the lungs of rats and humans compared to mice for the same TCE exposure conditions. An alternative assumption would have been that the activity of the enzyme responsible for the clearance of CHL scales in the same way as P450. This assumption would lead to similar concentrations of CHL in the lungs of mice, rats, and humans for the same TCE exposure conditions.
Parameters for conjugative metabolism. The parameters in the PBPK model for predicting the kidney dose metric are the production of DCVC by the GST pathway (KFC), its activation by 3-lyase (KBLC), and its clearance by N-acetyltransferase (KNATC). First-order rate constants are used because the production of metabolites by the GST pathway is quite low, and saturation of enzyme capacity is unlikely. As discussed earlier, the capacity and affinity of i-lyase in the kidney have been measured in both rats and humans (141) . These data were used to estimate the apparent first-order rate constants (KBLC) used in the model. No data were available on the activity of I-lyase in the mouse, so the relationships between P-lyase metabolic parameters in mice and rats reported for trichlorovinylcysteine derived from PERC (136) were assumed to apply-for DCVC as well. For N-acetyltransferase, only specific activity data across species are available (142) . These data were converted to the corresponding rate constants (KNATC) by assuming the affinity of N-acetyltransferase for DCVC is the same as that measured for ,B-lyase in the same species. This assumption is supported by the similarity of the affinities of N-acetyltransferase and I-lyase for DCVC in the rat: 3.3 mM and 1.6 mM, respectively (141, 150) .
Finally, measurements of oxidative and conjugative metabolites in the urine following TCE exposure (143) were used to obtain estimates of the GST pathway rate constant (KFC). The oxidative pathway was represented by total excretion of TCA plus TCOH, while the conjugative pathway was represented by excretion of 1,2-DCVC. Data from the same study on excretion of 2,2-DCVC were not used. Unlike 1,2-DCVC, there was no evidence of a dose response for 2,2-DCVC as a function of TCE exposure in humans or rodents; similar amounts of 2,2-DCVC were excreted for TCE exposures ranging from 40 to 160 ppm. Ignoring 2,2-DCVC is unlikely to significantly affect the risk assessment for TCE, since 1,2-DCVC is clearly the more toxic and mutagenic of the two isomers (151) .
The results of this analysis are shown in Table 2 . In performing this analysis, all of the parameters in the model were set at the default values except VMC, KM, and KFC (in particular, KBLC and KNATC were set to the values calculated as described above). The values of VMC, KM, and KFC in the model were then varied to bring the model into agreement with the data for both the oxidative (MFO) and conjugative (GST) pathways. It can be seen that the model could be made to agree quite well with the urinary data when allometric scaling was assumed for conjugative metabolism (i.e., using the same value of the scaled parameter KFC in rat and human). Although it was necessary to adjust KM to obtain the best agreement with the MFO pathway data, allometric scaling of conjugative metabolism also gave the best agreement with the GST pathway data when the default values for KM were used. This result is consistent with the observed allometric scaling of the GST pathway for methylene chloride (152) .
Additional data on urinary metabolite concentrations following oral gavage of rats with 50 mg/kg TCE (142), although not suitable for comparing with the model, were consistent with the inhalation data, suggesting that there is not an effect due to route of exposure. Therefore, the value estimated from inhalation was used to obtain the kidney dose metrics for the rat for both inhalation and oral exposures. Figure 4 compares the predictions of the model with experimental data on the concentrations of TCE in the blood and TCA in the plasma of male and female B6C3F1 mice exposed to 110 and 368 ppm, respectively, of TCE by inhalation for 4 hr (93) . The model overpredicts the blood concentrations of TCE during the exposure by about 50%, but provides a good description of the time course for TCA in the plasma. Figure  5 shows the ability of the model to simultaneously reproduce experimental data on the blood concentrations of TCE, TCA, and TCOH in mice exposed to 1,000 mg/kg TCE by corn oil gavage (50). The model is also able to simulate ( Figure 6 ) the time course ofTCE, TCA, TCOH, and DCA in the B6C3F, mouse following an oral dose of 499 mg/kg in an aqueous vehicle (126) . The DCA data at 6 and 9 hr in Figure 6 are suspect due to problems with the analytical method (129) . Figure  7 shows of the time course for TCA in the plasma of the female rats, and for both TCE and TCA in the male rats. Figure 9 shows the ability of the model to simultaneously reproduce experimental data on the blood concentrations of TCE, TCA, and TCOH in rats exposed to 1,000 mg/kg TCE by corn oil gavage (49) . As shown in Figures 10-13 , the model is also able to simuiate the time courses of TCE, TCA, and TCOH in the F344 rat following oral doses of 100, 197, 591, and 3,000 mg/kg in an aqueous vehicle (69, 113) . .g. 4.0 50 60 Tune (hours) 12 have essentially no impact on risk predictions based on the two dose metrics, and only 5 have a significant impact: the alveolar ventilation (QPC), the capacity for metabolism of TCE (VM), the fraction of TCA produced from the metabolism of TCE (PO), the volume of distribution (VDTCAC) and rate of excretion (KUTC) of TCA. None of the parameters are associated with sensitivities greater than 1.0, indicating that there is no amplification of error from the inputs of the model to the outputs. This is, of course, a desirable trait in a model to be used for risk assessment.
Sensitivities for the other metabolites in the model are not shown, but the results were similar to those for TCA; that is, none of the parameters were associated with sensitivities greater than 1 in absolute value, and (except for QPC) only the parameters directly related to the production and dearance of a metabolite were associated with significant sensitivities (close to 1) for dose metrics based on that metabolite.
PBPK Model Parameter Uncertainty
There are a number of ways of characterizing the uncertainty associated with use of a PBPK model. The best approach depends on the level of uncertainty. In the case of the TCE model, the level of uncertainty varies considerably from one portion of the model to another. Some dose metric value for a specified human exposure scenario. This process is repeated the specified number of times (400 in this case) until the distributions of dose metrics have been obtained. Table 4 lists the means and coefficients of variation (CV) used in a Monte Carlo uncertainty analysis of the AUC-TCA dose metric. Truncated (greater than zero) normal distributions were used for all parameters except the kinetic parameters, which were assumed to be log-normally distributed. The CVs for the physiological parameters were estimated from data on the variability of published values (146, 156 (6) . The CVs for the metabolic and kinetic The results of the Monte Carlo analysis are shown in Table 5 165, 66) . 0Doses employed in oral bioassay (59) . (25) bolically active Clara cells in the mouse than in the human (71) . Although no data could be found on the cross-species activity of ADH in for TCA in the lung, ADH activity in the rat airway ercentiles of appears to be restricted to the Clara cell (157), Ire generally suggesting that the enzymes responsible for the nean, and all clearance of CHL may also fall off more for the dose rapidly than allometric expectations.
less than an
The alternative dose metric calculations, ts are similar shown in parentheses in Table 6 , were del of meth-obtained under the assumption that the dearbly represen-ance of CHL scales in the same way as lung d with other P450. Using this assumption yields dose metrtions of the rics roughly 10-fold higher in the rat and JC-DCA (in 700-fold higher in the human. This signifiofTCE.
cant uncertainty regarding the relative expoest source of sure to CHL across species could be resolved lation of the by the collection of data on CHL dearance in data on the the lung across species, similar to the data in the lung. that have been reported on P450. Of course, dose metrics as discussed in the section on the lung parassays provid-meters, there are also other sources of paraors (64) (65) (66) , meter uncertainty associated with the lung be mouse, for dose metric. Additional experimental data are for several needed before a quantitative estimate of the he different overall uncertainty associated with this metric )rding to the could be confidently attempted.
Kidney dose metric. The overriding source of uncertainty regarding calculation of the kidney dose metric is the inadequate and often conflicting data in the literature for the conjugative pathway. Specific data gaps include the affinity of kidney N-acetyltransferase for DCVC in the human and the activities of the GST pathway in the rat and human. Table 7 shows the predicted kidney dose metrics for the principal bioassays providing a dose response for kidney tumors (65) (66) (67) , for the highest oral exposure of the mouse, and for several human exposure scenarios. The different exposures have been ordered according to the predicted value of the LADD based on the production of the toxic thiol per gram of kidney tissue (KTOX). The human dose metrics shown in Table 7 are those calculated assuming allometric scaling of the GSH pathway rate constant. There is, of course, additional parameter uncertainty associated with the limited data on the other enzymes involved in the production, intoxication, and clearance of DCVC. As with the lung target tissue, it will not be possible to provide an accurate assessment of the overall uncertainty in the kidney dose metric until reproducible data are collected.
Dose Metric Sdection Uncertainty
The pharmacokinetic dose metrics most commonly applied to characterize the exposure of a tissue to a chemical are the peak concentration and the AUC, and these are the principal types of dose metrics provided in the PBPK model. However, there are other possible forms for dose metrics that might be useful for describing nonlinear processes. For example, time above a critical concentration (TACC) has been suggested as an appropriate dose metric for the effects of methotrexate, whose toxicity demonstrates a strong dependence on dose rate (158 the pharmacokinetic dose metrics provided in the PBPK model and considers other possible dose metrics that could be selected.
Liver dose metric. If, as was once thought, reactive species produced during the metabolism of TCE were responsible for its liver carcinogenicity, an appropriate dose metric would be total daily metabolism divided by the volume of the liver (13.18 ). However, current information suggests that two stable metabolites, TCA and DCA, are primarily responsible for the liver tumor incidence observed in mice dosed with TCE (69, 70) . The commonly accepted form of the dose metric for the chronic interaction of a stable metabolite with a tissue is the AUC in the tissue. This mathematical form implicitly assumes that the cumulative effect of the metabolite on the tissue is linear over both concentration and time. In this case, the most appropriate dose metric would reflect liver tissue exposure (AUC) to both TCA and DCA (69, 70) . If it is assumed that both DCA and TCA contribute to the carcinogenicity of TCE in the liver, the proportion of the observed tumor risk to assign to each metabolite could be based on their relative potencies when dosed directly. However, as mentioned earlier, data on the AUCs for DCA resulting from exposures to TCA [e.g., (70) ] may have been compromised by a sampling artifact that could lead to overestimates of DCA concentrations in the presence of TCA (129) , making it impossible to estimate the individual potencies of TCA and DCA. As a simplifying assumption, all of the tumorigenicity of TCE can simply be ascribed to TCA, as was assumed by Fisher and Allen (25) . Since DCA has been detected in the mouse to a much greater extent than in the human following TCE exposure, the use of the AUC for TCA alone as the dose metric is almost certainly safe-sided (in the direction of overestimating the human risk estimate) compared to including potency-weighted AUCs for both TCA and DCA.
Strictly speaking, the AUC for TCA should actually be calculated for the concentration in the liver. However, the use of the AUC in the plasma provides a surrogate for the liver AUC that can be validated more readily against experimental data. Since risk estimates are based on the ratio of animal and human dose metrics, this effectively amounts to an assumption that the ratios of the plasma concentrations of the acids to their concentrations in the liver are constant across species. In fact, data on the binding of TCA in the plasma of rats and humans (113) suggest that TCA in plasma is bound to a much greater extent in the human (-80%) than in the rodent (-50%). Based on these data, it can be estimated that the liver-to-plasma TCA concentration ratio in the human is about 40% of the ratio in the rodent. This estimate is also consistent with the ratio of reported relative volumes of distribution of TCA in the two species, which are on the order of 10 and 25% of body weight in the human and rodent, respectively. Thus, using the AUC of TCA in the plasma as the dose metric provides a conservative estimate of the crossspecies relationship for the AUCs in the liver, tending to overestimate liver exposure to TCA in the human by about 2-fold. Table 8 shows the predicted liver dose metrics for the principal animal bioassays providing a dose response for liver tumors (59, (65) (66) (67) 159) , for the highest rat exposures in these same studies, and for several human exposure scenarios. The different exposures have been ordered according to the predicted value of the LADD based on the AUC for TCA. Bioassay exposures associated with LADDs for AUC-TCA of greater than 1,150 were uniformly positive, whereas bioassay exposures with LADDs less than 700 were uniformly negative. The highest exposures of rats produced AUC-LADDs considerably less than those producing tumors in the mouse, consistent with the negative results in the rat bioassays.
The most striking feature of the results for this target tissue compared to the lung and kidney is that two of the three highest dose metrics were obtained for the human occupational exposure scenarios. The relatively high dose metrics for AUC-TCA in the human reflect the much slower clearance of TCA compared to the rodent. It is interesting to note that the rank ordering in Table 8 would be different if it were based on AUC-DCA.
In that case, all of the human dose metrics would be uniformly below the positive animal bioassay dose metrics, reflecting the rapid clearance of DCA in the human.
Although AUC is a standard metric for tissue exposure, other forms of the dose metrics for DCA and TCA might be more appropriate for their modes of action. If it is possible that the tumorigenic effects of these chemicals are related to some aspect of their interaction with a receptor, peak concentrations (CMAX), or TACC, might actually be more appropriate than AUCs. Another nonlinear dose metric recently discussed for receptor-mediated effects is based on average receptor occupancy (160) . Unfortunately, the more an attempt is made to include pharmacodynamic events in a dose metric, the more difficult it becomes to collect the data necessary for its use. In the case of TCE, there are currently no experimental data available to evaluate the use of such alternative pharmacodynamic dose metric approaches. Of the possible dose metrics, only AUC, CMAX, and TACC can be estimated from the data currently available. All three of these metrics are available for TCA in the PBPK model.
Lung dose metric. As described earlier, tumors have been observed in the lungs of mice exposed to TCE by inhalation. The mechanism in this case appears to be entirely different from that in the liver. In a welldesigned experimental effort (71), investigators at ICI combined in vivo and in vitro experiments to elucidate the mechanism of TCE carcinogenicity in the mouse lung.
In the in vivo studies, female mice and rats were exposed to TCE at a range of inhaled concentrations at and below the concentrations at which lung tumors have been observed in mice, and the effects of TCE in the lung were determined. A specific lesion, characterized by vacuolization of lung Clara (162) . The fact that tumors are observed only in the rat might suggest that they are associated with the male rat nephropathy described for many hydrocarbons, in which the accumulation of a male-rat-specific a20-globulin in proximal tubular cells leads to hyaline droplet accumulation, necrosis, increased cell proliferation, and cancer (163) . However, a study designed specifically to evaluate this possibility showed evidence of the hyaline droplet accumulation and increased cell replication with PERC but not with TCE (163) . It was also felt that the oxidative metabolism of TCE was unlikely to explain the kidney carcinogenicity in rats, since the rate of metabolism in the liver greatly exceeds that in the kidney, and no liver tumors are seen in the rat (72) . An alternative mechanism was proposed, in which direct conjugation of TCE with GSH in the liver was followed by further metabolism in the kidney to a cysteine conjugate that could then be cleaved to a reactive intermediate in the kidney tubular cells (131) . The cysteine conjugate formed from TCE, DCVC, has been shown to be highly nephrotoxic (78) and mutagenic in the Ames test (115) .
As with the lung carcinogenicity of TCE, more than one mechanism may play a role in the kidney tumors. The tumors produced in the kidney by TCE are very rare tumors in control animals and do not appear to be associated with the exacerbation of spontaneous processes, suggesting that a genotoxic mechanism may be responsible. On the other hand, in the only bioassay that reported a significant increase in kidney tumors from TCE (67) , cytotoxicity was observed in the kidney at both the low and high doses, whereas tumors were observed only at the high dose. Kidney cytotoxicity was also reported in association with a nonstatistically significant incidence of kidney tumors in another study (65, 66) . However, dosing of mice with DCVC in drinking water for 46 weeks produced clear evidence of toxicity at 87 weeks but no evidence of tumors (164) . The significance of this result is enhanced by the observation that activation of DCVC in the kidney appears to be much greater in the mouse than in the rat, and the mouse also appears to be more responsive to the induction of cell proliferation by DCVC than the rat (138) . Moreover, measurements of acid-labile protein adducts in the kidney associated with DCVC suggest that the production of DCVC-derived reactive species in the kidney resulting from an oral dose of 1,000 mg/kg TCE may actually be greater in mice than in rats (137, 138) , and mice but not rats showed increased cell proliferation in the kidney in response to treatment with TCE at 1,000 mg/kg. Other studies in the rat also fail to support the suggestion that significant hyperplasia is produced in the kidney from exposure of rats to TCE (163) . Thus, whether a genotoxic or cytotoxic mechanism involving DCVC is proposed, it is difficult to explain either the negative results of the DCVC bioassay in the mouse or the greater sensitivity of the rat compared to the mouse with regard to kidney tumors from TCE. Nevertheless, a mode of action for TCE in the kidney involving mutagenicity and cytotoxicity from DCVC is the most supportable choice at present, especially since no suggestion for an alternative source of the observed tumorigenicity has been provided in any of the studies just described. The kidney dose metric calculations shown in Table 7 can be used to evaluate the consistency of the KTOX dose metric with the bioassay results. Bioassay exposures associated with KTOX LADDs greater than 15 tended to be positive, whereas bioassay exposures with KTOX LADDs less than 15 were negative. The mouse dose metric is well below that of the rat, consistent with bioassay results. The lower dose metric values in the mouse result from the higher ratio of clearance (KNATC) to intoxification (KBLC) in the mouse as compared to the rat.
Noncancer dose metrics. The issues associated with the selection of dose metrics for the noncancer toxicity of TCE are discussed in a companion article in this same issue (44) . Therefore, only a short summary of the rationale for the selection of noncancer dose metrics is included here. The relationship of various noncancer dose metrics across species is shown in Table 9 (73) have demonstrated that the relationship between the acute hepatotoxicity of TCE and the total production of urinary metabolites is linear, and it has been suggested that this result is consistent with the hypothesis that the toxicity is produced by reactive intermediates (13) . Based on this assumption, the most reasonable dose metric for the hepatic toxicity of TCE would be the total amount of metabolism divided by the volume of the liver (18) . On the other hand, a comparison of the toxic potency for TCE and PERC (73) suggests that TCA, rather than total metabolism, is responsible for the liver effects of these chemicals (44) .
Nephrotoxicity. As already discussed, the toxicity observed in the kidney appears to be due to metabolism of DCVC. Therefore, the cancer dose metric (KTOX) provides a useful metric for the kidney toxicity as well.
Immunological and developmental effects. Significant uncertainty exists regarding the appropriate dose metric for immunological and developmental effects. Possible metrics include the peak concentrations and AUCs for TCE and TCA. In the case of fetal effects, the dose metric would most properly be calculated using a PBPK model with a description of the fetus. However, dose metrics based on maternal blood should provide a reasonable surrogate for the effects of TCE, since TCE and its metabolites appear to move readily across the placenta (91) . The discussion in this article has been restricted primarily to pharmacokinetic issues. However, the line between pharmacokinetics and pharmacodynamics is ill defined, and a pharmacokinetic model can often be extended somewhat into the pharmacodynamic realm. The following discussion touches on some of the areas where there is potential to develop improved dose metrics for the PBPK model and that include some level of pharmacodynamics.
Liver. Evidence regarding the mode of action of TCA and DCA could potentially be used to develop a dose metric more closely associated with tumorigenicity. In principle, if information on the differential response across species to mitogenic effects from TCA and DCA were obtained, it could be incorporated into a pharmacodynamic tissue dose metric. Possible pharmacodynamic metrics in the case of the liver carcinogenicity of TCE might be the expression of TGF-3 or a measurable suppression of cell proliferation in hepatocytes as a marker of an early response to a presumed mitogenic signal. The use of a similar approach, based on the observed dose dependence of hormonal response, has been proposed for an analogous carcinogenic mechanism associated with follicular cell carcinoma in the thyroid (165) .
Lung and kidney. If the kidney and lung carcinogenicity of TCE is considered to result primarily from enhanced cell proliferation secondary to recurrent toxicity, possible dose metrics would include measures of cytotoxicity, cell death, or cell division, as has been proposed for the liver carcinogenicity of chloroform (35, 166) . In the case of chloroform, fairly complicated metrics involving the instantaneous rates of metabolism and distributions of cellular sensitivity have been suggested (5, 35) . To apply these approaches to (100) . Sex, pregnancy, and age-related differences in metabolism can result from normal variations in CYP 2E1 content (101) ; increased metabolism can result from the inducibility of CYP 1A1/2 (e.g., by aromatics), 2B1 (e.g., by phenobarbital), or 2E1 (e.g., by ethanol) (102, 115) . Studies of human populations have shown that the activity of the CYP enzymes can vary by more than a factor of 10 between individuals (152, 174, 175) , and that there is a genetic difference (polymorphism) between individuals with high activity and low activity that is associated with a different susceptibility to cancer (176) . Genetic polymorphisms of the CYP enzymes across racial and ethnic groups have been observed (177) , as have quantitative differences in metabolic capacity (178) .
Sex differences in the excretion of TCE metabolites have also been noted in the human (179) , with females excreting a larger proportion of TCA and a smaller proportion of TCOH than males. The difference between females and males in the ratio of TCA to TCOH excreted is greatest initially (as much as a factor of 5.5 during the first 24 hr after exposure), suggesting that the difference derives from a relatively greater rate of the production of TCA from CHL rather than from TCOH. The production of TCA in humans appears to be highly variable and generally somewhat higher than in other animals. For example, in one study the production of TCA from chloral hydrate in different individuals varied from 5 to 47% (107) .
There are still other factors such as disease and hormonal status that could also affect the individual risk from exposure to a TCE, either because of an impact on pharmacokinetics or metabolism, or due to other interactions. Estrogens, for example, have been associated with both increased risk (for breast cancer) and decreased risk (for colon cancer) and are also metabolized by the CYP system (175) . Therefore, the possibility of interaction with TCE exposure includes metabolic inhibition or induction as well as tumor promotion or repression.
Pharmacokinetic and metabolic differences alone cannot explain the overall interindividual variation in susceptibility observed in exposed populations (173, 180) . Clearly there are other, less well understood interindividual differences, both acquired (due to environmental exposures or disease states) and inherited (due to genetic differences) that are also important determinants of the individual risk for development of toxicity from exposure to a chemical. However, to the extent that we can quantitatively describe and evaluate pharmacokinetic and metabolic variation, it will become increasingly possible to estimate the range of risks in an exposed population and to identify the factors that put individuals at the greatest risk.
Conclusions
The PBPK model described in this article provides reasonably accurate and precise estimates of dose metrics based on TCE and its major metabolites, TCA, TCOH, and DGA, in both experimental animals and humans. Tissue 
